Women’s Health Research at Yale funds studies on pain relief, cannabis, and genetic origins of sex differences in disease
Women’s Health Research at Yale (WHRY) today announced funding for first-of-their-kind studies on pain relief, cannabis, and the genetic basis of sex differences across a broad range of ailments, including Alzheimer’s disease and heart disease.
Yale School of Medicine Joins Health Care Leaders to Advance Equity, Safety
Yale School of Medicine has joined a network of health care leaders organizing across industries to create safe, fair, and dignified workplaces for women. TIME’S UP Healthcare aims to drive new policies and decisions that result in more balanced, diverse, and accountable leadership; address workplace discrimination, harassment and abuse; and create equitable and safe work cultures within all facets of the healthcare industry.
Opioid epidemic responses overlook gender
In a commentary published in The Lancet, Women’s Health Research at Yale Director Carolyn M. Mazure, and Yale Program in Addiction Medicine Director David A. Fiellin, M.D., called for researchers, clinicians, and policymakers to account for the different ways in which women encounter opioid addiction and treatment.Source: Yale News
Poor and minority women face widening barriers to depression treatment
Megan Smith, DrPH, MPH, Associate Professor of Psychiatry and in the Child Study Center, is featured in a Connecticut Health Investigative Team story and podcast about depression in women and barriers to care.Source: Connecticut Health I-Team
Breast cancer care in U.S. territories lags behind care in states
Older women residing in the U.S territories are less likely to receive recommended or timely care for breast cancer compared with similar women residing in the continental United States, according to Yale researchers. Their findings were published in the March issue of Health Affairs.
Breast cancer breakthrough may have been found in Connecticut
A big breakthrough in the battle against breast cancer may have been found in Connecticut. The discovery was make by a local researcher and helped by a grant from the Terri Brodeur Breast Cancer Foundation with money raised by the Southern Connecticut Breast Cancer Walk. It starts with hundreds of walkers every fall and ends in a lab. The local fight against breast cancer is spearheaded by the foundation. "I feel like a lot of us clinicians have insight into what's going on with the disease type but it's very hard to compete with people who are doing research full time," said Dr. Erin Hofstatter, Yale Cancer Center. "Terri Brodeur has been valuable in giving me a chance."Source: WFSB
Yale’s advance in breast cancer surgery to be tested in nationwide study
Removing a small amount of extra tissue around a breast cancer tumor may keep a patient from having a recurrence of the cancer or of having to return to the operating table because not all of the malignant cells were removed in the first operation. That’s the theory that’s being tested in a nationwide clinical trial sponsored by the Yale Cancer Center called SHAVE2. Dr. Anees Chagpar, assistant director of global oncology at the Yale School of Medicine and former director of the Breast Center, is the principal investigator. Chagpar oversaw the first SHAVE trial at Yale, which involved 235 patients with stage 0 to stage 3 breast cancer who were given a partial mastectomy, also known as a lumpectomy. Some were given normal lumpectomies, while others had more tissue removed from around the tumor site, known as cavity shave margins.Source: New Haven Register
Frozen vs. fresh embryos for IVF? Study finds little impact on fertility
Many women struggling to have a baby turn to in-vitro fertilization to improve their chances, and then face further uncertainty and anxiety when confronted with the decision of whether to use frozen or fresh embryos. A new study by a researcher at Yale School of Public Health and co-authors in China finds an insignificant difference in live birth rates between the two methods.
Opportunities to vaccinate young women against HPV missed at alarming rate
en aged 18-26 who were eligible to receive Human Papilloma Virus (HPV) vaccine have missed at least one opportunity to receive the vaccine during a visit to an obstetrics and gynecology clinic, Yale researchers report. This study also confirms previous research showing racial disparities in vaccination for HPV: Women who identify as black are 61% more likely have had a missed opportunity than women who identify as white. These findings are published in the American Journal of Obstetrics and Gynecology. HPV is a well-known cause of pre-cancerous cervical lesions, which, if untreated, could develop into cervical cancer. Immunization against HPV has been shown to be safe and effective in preventing these pre-cancerous lesions. The two-dose HPV vaccine is recommended for administration to It is recommended that girls ages 11-12 receive the two-dose HPV vaccine, and that those through age 26 receive the three-dose vaccination for “catch-up.”